Company intelligence / Profile preview
Wingor Biotechnology
- Ownership
- Private
- Development stage
- Other
Overview
Wingor Biotechnology leads in IND applications for stem cell drugs in southern China, with at least one cell therapy program (Human cord derived MSC cell) reaching Phase 2 for indications such as acute ischemic stroke, androgen-insensitivity syndrome, acute respiratory distress syndrome, and acute-on-chronic liver failure. Multiple preclinical oncology and gene editing programs are ongoing. Four clinical cell therapy projects are approved with patient recruitment underway.[1][4][6][7]
- Therapeutic areas
- EndocrinologyGastroenterologyPulmonologyCardiovascularOncology
- Modalities
- Stem cell therapyGene editingCAR-T cell therapyExosome-based therapyMesenchymal stem cell therapy
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Wingor Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wingor Biotechnology.